Roberto F.
- Country
- Italy
- Department
- Oncology
Research Overview
- Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study
- A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy
- Phase 1b/2 Umbrella Study of MK-1084 and Combination Therapy in Patients With Previously Treated Advanced or Metastatic KRAS G12C-Mutated Nonsquamous NSCLC
Data & Insights
Has run more than one trial at 234 of 445 partner sites.
Specializations
Hormone Receptor‑Positive Breast Cancer
Focused on inoperable or metastatic hormone receptor‑positive, HER2‑negative breast cancer that has progressed after prior chemotherapy.
- Endocrine‑resistant disease
- PIK3CA‑mutated subtypes
- Chromosome 8p loss
Research conducted at Ospedale San Raffaele and the San Raffaele Scientific Institute.
Liver Metabolic and Cancer Disorders
Investigates non‑alcoholic steatohepatitis (NASH) and its progression to cirrhosis, hepatocellular carcinoma, and end‑stage liver disease.
- Metabolic risk factors (obesity, T2DM)
- Fibrosis and inflammation pathways
- Advanced hepatocellular carcinoma therapies
Integrates metabolic and oncologic expertise within the oncology department.
Lung Cancer Subtypes
Encompasses both non‑small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), including ALK‑positive and HER2‑mutated forms.
- Targeted therapies for EGFR and KRAS G12C mutations
- Immunotherapy combinations
- Biomarker‑driven patient selection
Clinical activity spans early‑stage and advanced disease settings.
Gynecologic and Reproductive Cancers
Targets endometrial carcinoma, cervical squamous cell carcinoma, vulvar carcinoma, and ovarian malignancies.
- Mismatch repair‑deficient and MSI‑high tumors
- FGFR3‑altered urothelial and gynecologic cancers
- BRCA‑mutated ovarian cancer strategies
Studies include both localized and metastatic disease cohorts.
Hematologic Malignancies
Focuses on aggressive blood cancers such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and various B‑cell lymphomas.
- Targeted agents for TP53‑wildtype and del(17p) disease
- Combination regimens with BTK inhibitors
- Post‑transplant relapse prevention
Research leverages the institute’s transplant and cellular therapy platforms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.